targeted radiotherapy
Actinium Discloses NYSE Listing Deficiency, Patent Gains
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced on August 14 a mix of intellectual property and manufacturing progress for its lead radiotherapy candidate Actimab-A, alongside a separate and more consequential disclosure: NYSE Regulation has accepted the company’s plan to regain compliance with the exchange’s continued listing standards, after confirming Actinium is not currently meeting two…
